Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression

V. Brynychová, V. Hlaváč, M. Ehrlichová, R. Václavíková, V. Pecha, M. Trnková, M. Wald, M. Mrhalová, K. Kubáčková, T. Pikus, R. Kodet, J. Kovář, P. Souček,

. 2013 ; 9 (3) : 427-438.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NT13679 MZ0 CEP Register

Digital library NLK
Full text - Article
Source

E-resources Online Full text

NLK ProQuest Central from 2005-02-01 to 2020-12-31
Health & Medicine (ProQuest) from 2005-02-01 to 2020-12-31

AIM: A role of caspase-2 in chemotherapy-induced apoptosis has been suggested. Our study aimed to evaluate the prognostic and predictive importance of caspase-2 isoforms in breast cancer patients. MATERIALS & METHODS: Caspase-2L and -2S transcript levels were determined in paired tumor and non-malignant control tissues from 64 patients after neoadjuvant chemotherapy and 100 pretreatment patients (general set) by real-time PCR with absolute quantification. RESULTS: Low but statistically significant upregulation of caspase-2L in tumor versus control tissues was observed in both sets. Significant associations of the levels of caspase-2L, -2S or S/L ratio with clinical prognostic factors were observed. However, none of these associations were confirmed in both sets. Levels of caspase-2 isoforms or the S/L ratio did not significantly associate with progression-free survival in the general set or with chemotherapy response in the neoadjuvant set. CONCLUSION: Our results suggest that the role of caspase-2 isoforms in the progression of breast cancer may considerably differ between pre- and post-chemotherapy patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13031554
003      
CZ-PrNML
005      
20190514125727.0
007      
ta
008      
131002s2013 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/fon.12.200 $2 doi
035    __
$a (PubMed)23469978
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Brynychová, Veronika $u Toxicogenomics Unit, Department of Toxicology & Safety, National Institute of Public Health, Srobarova 48, 100 42, Prague 10, Czech Republic. $7 xx0323150
245    10
$a Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression / $c V. Brynychová, V. Hlaváč, M. Ehrlichová, R. Václavíková, V. Pecha, M. Trnková, M. Wald, M. Mrhalová, K. Kubáčková, T. Pikus, R. Kodet, J. Kovář, P. Souček,
520    9_
$a AIM: A role of caspase-2 in chemotherapy-induced apoptosis has been suggested. Our study aimed to evaluate the prognostic and predictive importance of caspase-2 isoforms in breast cancer patients. MATERIALS & METHODS: Caspase-2L and -2S transcript levels were determined in paired tumor and non-malignant control tissues from 64 patients after neoadjuvant chemotherapy and 100 pretreatment patients (general set) by real-time PCR with absolute quantification. RESULTS: Low but statistically significant upregulation of caspase-2L in tumor versus control tissues was observed in both sets. Significant associations of the levels of caspase-2L, -2S or S/L ratio with clinical prognostic factors were observed. However, none of these associations were confirmed in both sets. Levels of caspase-2 isoforms or the S/L ratio did not significantly associate with progression-free survival in the general set or with chemotherapy response in the neoadjuvant set. CONCLUSION: Our results suggest that the role of caspase-2 isoforms in the progression of breast cancer may considerably differ between pre- and post-chemotherapy patients.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádory prsu $x enzymologie $x mortalita $7 D001943
650    _2
$a duktální karcinom prsu $x enzymologie $x mortalita $7 D018270
650    _2
$a kaspasa 2 $x genetika $x metabolismus $7 D053143
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a cysteinové endopeptidasy $x genetika $x metabolismus $7 D003546
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a frekvence genu $7 D005787
650    _2
$a lidé $7 D006801
650    _2
$a izoenzymy $x genetika $x metabolismus $7 D007527
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a sekvenční analýza DNA $7 D017422
650    _2
$a upregulace $7 D015854
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hlaváč, Viktor $u - $7 xx0270481
700    1_
$a Ehrlichová, Marie $u - $7 xx0067467
700    1_
$a Václavíková, Radka $u - $7 xx0142918
700    1_
$a Pecha, Václav, $u - $d 1948- $7 xx0103675
700    1_
$a Trnková, Markéta $u - $7 xx0158385
700    1_
$a Wald, Martin, $u - $d 1955- $7 xx0107584
700    1_
$a Mrhalová, Marcela $u - $7 xx0062381
700    1_
$a Kubáčková, Kateřina $u - $7 xx0083614
700    1_
$a Pikus, Tomáš $u - $7 xx0169600
700    1_
$a Kodet, Roman, $u - $d 1953- $7 nlk19990073380
700    1_
$a Kovář, Jan, $u - $d 1952- $7 jn20040114001
700    1_
$a Souček, Pavel $u - $7 xx0060511
773    0_
$w MED00008687 $t Future oncology (London, England) $x 1744-8301 $g Roč. 9, č. 3 (2013), s. 427-438
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23469978 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20131002 $b ABA008
991    __
$a 20190514125831 $b ABA008
999    __
$a ok $b bmc $g 995641 $s 829999
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 9 $c 3 $d 427-438 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
GRA    __
$a NT13679 $p MZ0
LZP    __
$a Pubmed-20131002

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...